As in the above experiment, SBRT followed by αPD-1 + CCR2/5i conferred a significantly better control of primary pancreatic tumor growth compared with the other treatments tested (Figs. 3 B and S3 E). This evidence concerns the gene CCR2 and pancreatic neoplasm.